Abstract
Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems.
Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.
Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities.
Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.
Keywords: Biotherapy, cancer stem cell, drug combination, drug resistance, neoplasm metastasis, personalized cancer therapy.
Reviews on Recent Clinical Trials
Title:Drug Combination in Clinical Cancer Treatments
Volume: 12 Issue: 3
Author(s): Da-Yong Lu*, Ting-Ren Lu, Nagendra Sastry Yarla, Hong-Ying Wu, Bin Xu, Jian Ding and Hong Zhu
Affiliation:
- School of Life Sciences, Shanghai University, Shanghai 200444,China
Keywords: Biotherapy, cancer stem cell, drug combination, drug resistance, neoplasm metastasis, personalized cancer therapy.
Abstract: Aim: The modality of anticancer drug combinations needs to be renovated from empirical into technical-supportive systems.
Methods: To challenge past therapeutic routines, the new landscape may be established. Among the different areas of anticancer drug combination study, research in the fields of medical study is the most important one-including disciplinary of therapeutics in different cancer stages, modern genetic/ molecular diagnostics, cancer bioinformatics, traditional Chinese medicine, mathematical data analysis, therapeutic toxicity monitor, personalized cancer medicine and so on.
Discussion: This article addresses these types of cancer therapeutic management systems for clinical anticancer drug combination utilities.
Conclusion: Future cancer drug combinational studies and clinical optimums must be implemented.
Export Options
About this article
Cite this article as:
Lu Da-Yong*, Lu Ting-Ren , Yarla Sastry Nagendra , Wu Hong-Ying , Xu Bin , Ding Jian and Zhu Hong , Drug Combination in Clinical Cancer Treatments, Reviews on Recent Clinical Trials 2017; 12 (3) . https://dx.doi.org/10.2174/1574887112666170803145955
DOI https://dx.doi.org/10.2174/1574887112666170803145955 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma
Current Cancer Drug Targets Cytogenetic and Molecular Abnormalities in Myelodysplastic Syndrome
Current Molecular Medicine Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy
Current Cancer Drug Targets A novel NGR-conjugated peptide targets DNA damage responses for radiosensitization
Current Cancer Drug Targets A Comparative Study Among Various Statistical Tests Using Microarray Gene Expression Data
Current Bioinformatics Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Principal Physicochemical Methods Used to Characterize Dendrimer Molecule Complexes Used as Genetic Therapy Agents, Nanovaccines or Drug Carriers
Current Pharmaceutical Design Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism
Current Drug Metabolism The History of the HSV Amplicon: From Naturally Occurring Defective Genomes to Engineered Amplicon Vectors
Current Gene Therapy Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Functional Food: Product Development and Health Benefits
Recent Patents on Engineering Targeting Angiogenesis in Gastro-Intestinal Non Colorectal Cancers; A Review
Current Angiogenesis (Discontinued) Role of microRNAs in Vascular Remodeling
Current Molecular Medicine From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design The Role of microRNA-126 in Vascular Homeostasis
Current Vascular Pharmacology Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Nano-Carriers of Combination Tumor Physical Stimuli-Responsive Therapies
Current Drug Delivery